IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.

10/736,535

Applicant

Michael G. Tal

Filed

12/17/2003

Group Art Unit:

3731

Examiner

Nguyen

Docket No. :

TAL-001

Customer No.:

021884

Title

VASCULAR ABLATION APPARATUS AND METHOD

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 CFR § 1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application.

- 1.

 Enclosures accompanying this Information Disclosure Statement are:
 - 1a. ⊠ Form PTO-1449.
 - 1b. \(\Bigcia \) Copy(ies) of IDS citation(s), except for U.S. Patents and U.S. Patent Application publications for applications filed on or after June 30, 2003.
 - 1.c.

 English language copy of a communication(s) from a foreign Patent Office or a PCT International Search Report.
 - 1d.

 English language translation (complete, Abstract, or relevant portion(s)) attached to non-English language publications as indicated on the attached PTO Form PTO-1449.

	1e.		Explanations of Relevancy of References (ATTACHMENT 1(e), hereto) for providing a concise explanation of non-English publications.		
	1f.		List of Copending Applications (ATTACHMENT 1(f), hereto).		
	11. 1g.		List of Additional Submitted Documents (ATTACHMENT 1(g), hereto).		
	18.	ш	List of Additional Submitted Documents (ATTTACTIVILIAT 1(g), nereto).		
2.	☐ This]	Informa	tion Disclosure Statement is filed under 37 CFR § 1.97(b):		
			(Check either Item 2a or 2b or 2c or 2d)		
	2a.		Within three months of the filing date of a national application;		
	2b.		Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application.		
	2c.		Before the mailing of a first Office Action on the merits; or		
	2d.		Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.		
3.	☐ This Information Disclosure Statement is filed under 37 CFR § 1.97(c) after the period specified in paragraph 2 above but before the mailing date of any of a Final Office Action under § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise closes prosecution in the application, AND neck either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months)				
(0,,	3a. 3b.		The § 1.97 (e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 CFR § 1.17(p) is: □ enclosed.		
			to be charged to Deposit Account No. 01-2221.		
4.			cion Disclosure Statement is filed under 37 CFR § 1.97(d) after the period graph 3 above, but on or before payment of the Issue Fee, AND The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 CFR § 1.17(p) is: □ enclosed.		
			☐ to be charged to Deposit Account No. 01-2221.		
5.	□ Statement under § 1.97(e) (applicable if Item 3a or 4a is checked) (Check either Item 5a or 5b)				
	5a.		In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.		
	5b.		In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was first		

cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

6.	This is a continuation/division/continuation-in-part application under 37 CFR § 1.53(b). Any copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application(s) to which priority has been claimed, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR § 1.98(d); and similarly any copies of the publications listed on the attached Form PTO-1449 which were not previously cited in the prior application, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith.						
7.	☐ This is a Request for Continued Examination under 37 CFR § 1.114. (Check either Item 7a or 7b)						
	7a.	\boxtimes	The Issue Fee has not been paid.				
	7b.		A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A Request for Continued Examination under 37 CFR § 1.114, after payment of Issue Fee, is proper in accordance with 37 CFR § 1.114(a), respectively.				
8.	□ This	☐ This is a Supplemental Information Disclosure Statement (Check either Item 8a or 8b)					
	8a.		This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been				
	8b.		corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can be considered as if properly filed on This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR §§ 1.97 and 1.98, mailed				
9.			te with 37 CFR § 1.98, concise explanation of what is presently understood evance of each non-English publication is: (Check appropriate Items 9a, 9b, 9c and/or 9d)				
	9a.		satisfied for the non-English language publication(s) cited on the enclosed "English language version of the search report or action which				

	indicates the degree of relevance found by the foreign office". (See
	MPEP § 609, Minimum Requirements for an Information Disclosure
	Statement, Part A(3): Concise Explanation of the Relevance, 8th Ed.,
	Rev. 2)
9b.	set forth in the application.
9c.	satisfied for the non-English language publication(s) indicated on the
	attached Form PTO-1449 as having an English language translation
	(complete or relevant portion(s)) attached thereto.
9d.	enclosed as Attachment 1(e), hereto.

- 10. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart application or a PCT International Search Report, if submitted herewith). 37 CFR §§ 1.97(g) and (h).
- 11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account 01-2221.

Respectfully submitted,

Howard N. Flaxman

Registration No. 34,595

WELSH & FLAXMAN LLC 2000 Duke Street, Ste. 100 Alexandria, VA 22314 (703) 920-1122